TrialThe Journal of antimicrobial chemotherapy2019

Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.

Thomas Kaindl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.